Carrier Protein

Role of Carrier Proteins

Carrier proteins serve multiple functions in drug delivery:

Function	Impact on Drug
Transport	Carries drug through bloodstream
Protection	Shields from enzymatic degradation
Reservoir	Creates depot of bound drug
Distribution	Affects where drug goes in body
Half-life extension	Slows elimination

The balance between protein-bound and free drug determines therapeutic effect.

Key Carrier Proteins for Peptides

Albumin

The most abundant plasma protein:

• Concentration: 35-50 g/L in blood
• Half-life: ~19 days
• Binding capacity: Multiple binding sites
• Importance: Primary carrier for many drugs

Other Important Carriers

Protein	Primary Cargo
Transthyretin	Thyroid hormones, retinol
Sex hormone-binding globulin (SHBG)	Testosterone, estradiol
Corticosteroid-binding globulin	Cortisol
IGF-binding proteins (IGFBPs)	IGF-1, IGF-2
Growth hormone-binding protein	Growth hormone

Free vs Bound Drug

The Binding Equilibrium

When a drug enters blood:

• Some molecules bind to carrier proteins (bound fraction)
• Some remain unbound (free fraction)
• Only free drug can cross membranes and act on targets
• Equilibrium constantly shifts as free drug is used

Clinical Significance

Aspect	High Protein Binding	Low Protein Binding
Free drug	Small percentage	Large percentage
Half-life	Usually longer	Usually shorter
Peak effect	More gradual	More rapid
Drug interactions	More significant	Less significant
Dose adjustment in low albumin	May be needed	Less critical

Carrier Proteins and Peptide Design

Albumin-Binding Peptides

Modern peptide drugs are often designed to bind albumin:

Semaglutide example:

• Fatty acid chain (C18) attached to peptide
• Fatty acid binds to albumin
• Result: Half-life extended from minutes to ~7 days
• Enables once-weekly dosing

Liraglutide:

• Similar fatty acid modification (C16)
• Half-life: ~13 hours (daily dosing)
• Shorter chain = shorter half-life

Design Strategies

1. Lipidation - Attach fatty acid that binds albumin
2. Albumin fusion - Directly fuse peptide to albumin
3. Albumin-binding domains - Add protein segment that binds albumin
4. PEGylation - Polymer attachment (different mechanism but similar effect)

Albumin Binding in Peptide Therapy

GLP-1 Agonists

Drug	Albumin Strategy	Half-life	Dosing
Exenatide	None	2.4 hours	Twice daily
Liraglutide	C16 fatty acid	13 hours	Daily
Semaglutide	C18 fatty acid	7 days	Weekly
Tirzepatide	C20 fatty acid	5 days	Weekly

The correlation between albumin binding and half-life is clear.

Growth Hormone Pathway

• GH binds to GH-binding protein (GHBP)
• IGF-1 binds to IGF-binding proteins (IGFBPs)
• These carriers modulate hormone action
• IGFBP levels affect free IGF-1 availability

Clinical Implications

Drug Interactions

Drugs competing for same binding sites:

• One drug may displace another
• Suddenly increased free drug levels
• Potential for enhanced effects or toxicity
• More relevant for highly protein-bound drugs

Low Albumin States

Conditions with reduced albumin:

• Liver disease
• Kidney disease (nephrotic syndrome)
• Malnutrition
• Severe burns

Effects on drug therapy:

• Higher free drug fraction
• Potentially increased effect or toxicity
• May require dose adjustment

Implications for Peptide Therapy

Most peptide therapies:

• Dosed to achieve desired effect regardless of binding
• GLP-1 agonists titrated to response
• Binding helps but isn’t the only factor
• Individual variation in response expected

Natural Carrier Proteins for Hormones

Growth Hormone and IGF-1 System

Complex carrier protein network:

• GHBP - Carries ~50% of circulating GH
• IGFBP-3 - Primary IGF-1 carrier
• ALS (Acid Labile Subunit) - Forms ternary complex
• Result - IGF-1 half-life extended from minutes to hours

Implications for Peptide Secretagogues

When using GH-releasing peptides:

• Released GH binds to GHBP
• GH stimulates IGF-1 production
• IGF-1 bound by IGFBPs
• Carrier proteins modulate the entire cascade

Frequently Asked Questions

Does albumin binding mean less drug is working?

Not exactly. While only free drug acts immediately, bound drug serves as a reservoir that’s continuously released. This creates stable drug levels over time. The total amount of drug eventually becomes available - it’s just spread out over a longer period.

Why don’t all peptide drugs use albumin binding?

Some therapeutic situations require rapid onset or short duration of action. Albumin binding isn’t always desirable. Also, the technology to reliably achieve albumin binding while maintaining peptide activity is complex and not universally applicable.

Can albumin levels affect my peptide therapy response?

For most patients with normal albumin, this isn’t a significant concern. In conditions with very low albumin, there may be changes in drug distribution and effect. Your healthcare provider can adjust dosing if needed based on your clinical response.